Solar 18 Corporation (SLRN)
May 21, 2025 - SLRN was delisted (reason: merged into ALMS)
2.250
-0.020 (-0.88%)
Inactive · Last trade price on May 21, 2025
Theseus Pharmaceuticals Revenue
In the year 2005, Acelyrin had annual revenue of $250.00M.
Revenue (ttm)
$250.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
83
Market Cap
n/a
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2005 | 250.00M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSLRN News
- 2 months ago - ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - GlobeNewsWire
- 3 months ago - Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis - GlobeNewsWire
- 3 months ago - ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis - GlobeNewsWire
- 3 months ago - ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN - Business Wire
- 5 months ago - ACELYRIN Adopts Limited-Duration Stockholder Rights Plan - GlobeNewsWire
- 5 months ago - ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger - GlobeNewsWire
- 5 months ago - ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger - GlobeNewsWire
- 5 months ago - ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences - GlobeNewsWire